← Search & browse all drugs

vinblastine

L01CA01

Forms & Strengths

vinblastine sulfate injection: 1 mg/mL
lyophilized powder for injection: 10 mg vial
10 mg/mL in 10 mL or 25 mL vials

Adult Dosing

testicular cancer: 0.1-0.2 mg/kg IV on days 1 and 2, repeat every 3-4 weeks
Hodgkin's lymphoma: 6 mg/m2 IV on days 1 and 14 of 28-day cycle
non-Hodgkin's lymphoma: 1.4-1.8 mg/m2 IV on days 1 and 14 of 28-day cycle
dosage individualized based on clinical response and tolerance

Pediatric Dosing

children with Hodgkin's lymphoma: 2.5-6.0 mg/m2 IV on days 1 and 14 of 28-day cycle
children with non-Hodgkin's lymphoma: 1.4-1.8 mg/m2 IV on days 1 and 14 of 28-day cycle
children with testicular cancer: 0.1-0.2 mg/kg IV on days 1 and 2, repeat every 3-4 weeks
dosage individualized based on clinical response and tolerance

Indications

treatment of Hodgkin's lymphoma
treatment of non-Hodgkin's lymphoma
treatment of testicular cancer
treatment of breast cancer
treatment of Kaposi's sarcoma

Mechanism of Action

inhibits microtubule formation in the mitotic spindle
disrupts mitotic spindle activity, resulting in cell cycle arrest at metaphase
induces apoptosis in sensitive tumor cells

Contraindications

hypersensitivity to vinblastine or other vinca alkaloids
granulocytopenia
bacterial infection
pregnancy and lactation
myelosuppression

Adverse Reactions

bone marrow suppression (leukopenia, thrombocytopenia, anemia)
neutropenia
gastrointestinal disturbances (nausea, vomiting, diarrhea)
neurotoxicity (peripheral neuropathy, constipation)
alopecia

Drug Interactions

cisplatin: increased risk of neuromuscular toxicity
doxorubicin: enhanced cardiotoxicity
mitomycin-C: increased risk of myelosuppression
sulfonamides: potential for granulocytopenia
azole antifungals: potential for increased vinblastine toxicity

Curated Content: Needs Vetting Before Put to Clinical Use